Compound vaccine composition for preventing and controlling human viral infection, compound vaccine vaginal mist and uses thereof

Abstract

The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. The product of the present invention can prevent cervical cancer and treat HPV infection; it is suitable for married women of any age; it can prevent and treat chronic cervicitis and cervical epithelial dysplasia caused by sexually transmitted HPV infection, including CIN I, II, III Degree, inhibit HPV reproduction, prevent cervical cancer.

Description

technical field [0001] The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. Background technique [0002] Human papillomavirus (HPV) is the most common pathogen of sexually transmitted diseases. Recent reports indicate that more than half of adults in the world are infected by HPV, and about 30% are transmitted through sexual transmission. It has been reported that, unlike other sexually transmitted diseases, HPV is easily transmitted through direct contact with infected skin or with contaminated items. Because the virus lives within the outer skin cells of the genital tract and within the cells of the vagina, cervix, anus, and urethra, condoms do not protect against transmission in all of these areas, so so-called safe sex does not prevent HPV transmission. HPV infection is ve...

AI Technical Summary

Problems solved by technology

GARDASIL can also prevent sexual warts and low-grade cervical lesions (CIN 1) caused by HPV6, 11, 16 and 18, and is approved for women aged 9-26, although GARDASIL is a quadrivalent vaccine that can prevent HPV6, 11 , 16 and 18 infection, prevention of cervical cancer and sexual warts, the US FDA approved for women aged 9-26, there are still the following problems: 1. There are more than 100 types of HPV, GARDASIL vaccine can prevent HPV6, 11 , 16 and 18, but has no effect on other HPV types

Moreover, due to the suppression of HPV6, 11, 16 and 18, according to the principle of virus interference, it is likely to promote other types of HPV infections in the vagina and cervix; 2. GARDASIL vaccine has no effect on existing HPV6, 11, 16 and 18 infections Therapeutic effect; 3. The age group of GARDASIL vaccine is 9-26 years old, and it is powerless against HPV infection of married women over 26 years old; 4. The immunization procedure of GARDASIL vaccine is to inoculate the upper arm intramuscularly 3 times within 6 months, it is recommended The usage is: take the first shot on the selected date, take the second shot 2 months later, and take the third shot 6 months after the first shot

Therefore, the application of GARDASIL vaccine injection is not conducive to the promotion

Local immunization of vaginal mucosa, painless, easy to accept, and good compliance; 5. GARDASIL vaccine can only produce systemic immunity, while HPV infection of vagina and cervix is ​​local mucosal infection; therefore, local mucosal immunity is more important than systemic immunity; 6 .Vaginal mucosal immunization has a broad antigen cross-protection spectrum; 7.GARDASIL vaccine is expensive, each dose is 120 US dollars, and a complete immunization program requires 360 US dollars. The vast number of developing countries obviously cannot afford such a high cost